- Order a PDF
New Haven biopharma Kolltan Pharmaceuticals said it has licensed antibody technology developed by one of its founders and a member of its scientific advisory board.
The so-called anti-KIT receptor tyrosine kinase antibodies were developed in the labs of Joseph Schlessinger at Yale University — a Kolltan founder — and Sachdev Sidu, a geneticist at the University of Toronto and Kolltan adviser.
Terms of the deal were not disclosed.
Comments
Sign up now for our daily and weekly
ADVERTISEMENTS
Private equity firm made unsolicited XL Center bid
Chambers combines passion for music, fitness into up-tempo, high-intensity gym
New Trinity Health CEO pledges community approach in competitive healthcare market
Connecticut Water rebuffs Eversource's late takeover bid
Amid funding crunch, CT colleges look to diversify revenue streams